Blueprint Historical Financial Ratios
| BPMC Stock | USD 90.46 0.13 0.14% |
Blueprint Medicines is presently reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 44.91 or Days Sales Outstanding of 69.1 will help investors to properly organize and evaluate Blueprint Medicines Corp financial condition quickly.
Blueprint |
About Blueprint Financial Ratios Analysis
Blueprint Medicines CorpFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Blueprint Medicines investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Blueprint financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Blueprint Medicines history.
Blueprint Medicines Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Blueprint Medicines Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Blueprint Medicines sales, a figure that is much harder to manipulate than other Blueprint Medicines Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Blueprint Medicines' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Blueprint Medicines Corp current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At present, Blueprint Medicines' Days Sales Outstanding is projected to decrease significantly based on the last few years of reporting. The current year's Stock Based Compensation To Revenue is expected to grow to 0.52, whereas Price To Sales Ratio is forecasted to decline to 21.28.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 64.09 | 42.6 | 20.16 | 25.94 | Receivables Turnover | 4.86 | 5.52 | 5.78 | 5.49 |
Blueprint Medicines fundamentals Correlations
Click cells to compare fundamentals
Blueprint Medicines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Blueprint Medicines fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 57.61 | 7.71 | 34.81 | 12.81 | 22.4 | 21.28 | |
| Ptb Ratio | 8.25 | 4.16 | 6.46 | 5.08 | 42.77 | 44.91 | |
| Days Sales Outstanding | 128.48 | 11.64 | 75.06 | 66.08 | 63.2 | 69.1 | |
| Book Value Per Share | 9.71 | 26.96 | 16.59 | 8.63 | 2.16 | 2.05 | |
| Free Cash Flow Yield | (0.0762) | 0.0628 | (0.0893) | (0.2) | (0.0811) | (0.0851) | |
| Operating Cash Flow Per Share | (5.81) | 7.1 | (5.1) | (8.42) | (7.21) | (6.85) | |
| Stock Based Compensation To Revenue | 0.82 | 0.0952 | 0.51 | 0.49 | 0.37 | 0.52 | |
| Capex To Depreciation | 2.66 | 0.48 | 40.32 | 0.76 | 1.38 | 1.31 | |
| Pb Ratio | 8.25 | 4.16 | 6.46 | 5.08 | 42.77 | 44.91 | |
| Ev To Sales | 57.34 | 6.96 | 34.26 | 13.41 | 25.22 | 41.29 | |
| Free Cash Flow Per Share | (6.11) | 7.04 | (9.57) | (8.57) | (7.48) | (7.85) | |
| Roic | (0.74) | 0.2 | (0.67) | (0.85) | (0.6) | (0.63) | |
| Net Income Per Share | (6.87) | 5.76 | (11.01) | (9.35) | (8.37) | (8.79) | |
| Sales General And Administrative To Revenue | 1.08 | 1.45 | 0.19 | 1.01 | 1.07 | 1.12 | |
| Research And Ddevelopement To Revenue | 4.98 | 0.41 | 3.34 | 2.34 | 1.72 | 1.63 | |
| Capex To Revenue | 0.21 | 0.00398 | 1.45 | 0.0437 | 0.0644 | 0.0612 | |
| Cash Per Share | 10.11 | 15.99 | 8.15 | 15.84 | 11.73 | 9.2 | |
| Pocfratio | (13.78) | 15.8 | (20.99) | (5.2) | (12.79) | (13.43) | |
| Interest Coverage | (676.36) | (3.4K) | (26.7) | (32.76) | (37.67) | (39.56) | |
| Capex To Operating Cash Flow | (0.0504) | 0.008162 | (0.87) | (0.0178) | (0.0368) | (0.0386) | |
| Pfcf Ratio | (13.12) | 15.93 | (11.19) | (5.11) | (12.33) | (12.95) | |
| Income Quality | 0.8 | 1.23 | 0.46 | 0.9 | 0.86 | 0.62 | |
| Roe | (0.71) | 0.21 | (0.66) | (1.08) | (3.88) | (3.69) | |
| Ev To Operating Cash Flow | (13.72) | 14.26 | (20.66) | (5.45) | (14.4) | (15.12) | |
| Pe Ratio | (11.66) | 19.48 | (9.73) | (4.69) | (11.02) | (11.57) | |
| Return On Tangible Assets | (0.44) | (0.46) | 0.18 | (0.51) | (0.41) | (0.48) | |
| Ev To Free Cash Flow | (13.06) | 14.38 | (11.02) | (5.35) | (13.89) | (14.58) | |
| Earnings Yield | (0.1) | (0.0858) | 0.0513 | (0.21) | (0.0908) | (0.0953) | |
| Net Debt To E B I T D A | 0.0505 | (1.93) | 0.16 | (0.24) | (1.49) | (1.42) | |
| Current Ratio | 4.85 | 7.09 | 3.7 | 5.71 | 3.76 | 7.41 | |
| Tangible Book Value Per Share | 9.71 | 26.96 | 16.59 | 8.63 | 2.16 | 2.05 | |
| Receivables Turnover | 2.84 | 31.36 | 4.86 | 5.52 | 5.78 | 5.49 | |
| Graham Number | 38.75 | 59.09 | 64.09 | 42.6 | 20.16 | 25.94 | |
| Shareholders Equity Per Share | 9.71 | 26.96 | 16.59 | 8.63 | 2.16 | 2.05 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 6.986 | Quarterly Revenue Growth 1.266 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.